AstraZeneca's Lung-Cancer Drug Gets EU Approval
May 28 2021 - 2:44AM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC said Friday that its Tagrisso drug has been
approved in the European Union to treat early stages of lung
cancer.
The pharmaceutical company said the results from the Adaura
Phase 3 trial showed that Tagrisso reduced the risk of disease
recurrence or death by 80%.
Tagrisso has now been approved in more than 50 countries,
including the U.S. and China, AstraZeneca said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 28, 2021 02:29 ET (06:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
